Compare TARA & XSLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TARA | XSLL |
|---|---|---|
| Founded | N/A | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.9M | 271.8M |
| IPO Year | 2014 | 2026 |
| Metric | TARA | XSLL |
|---|---|---|
| Price | $5.47 | $9.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.40 | N/A |
| AVG Volume (30 Days) | ★ 572.7K | 56.4K |
| Earning Date | 05-01-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.25 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,948,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.77 | $9.80 |
| 52 Week High | $7.82 | $9.86 |
| Indicator | TARA | XSLL |
|---|---|---|
| Relative Strength Index (RSI) | 55.16 | 59.78 |
| Support Level | $4.92 | $9.83 |
| Resistance Level | $5.47 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 72.46 | 100.00 |
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Xsolla SPAC 1 is a blank check company.